Product Images Memantine Hydrochloride

This is a graph showing the time course of clinical improvement and decline in patients completing 28 weeks of treatment with Placebo and Memantine Hydrochloride. The change from baseline in ADCS-ADL score is plotted on the y-axis against the number of weeks of treatment on the x-axis.*

The figure labeled "Figure 2" shows the cumulative percentage of patients who completed 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. The text includes the names of two drugs - Placebo and Memantine Hydrochloride.*

This is a graph displaying the time course of change from baseline in SIB Score for patients who completed 28 weeks of treatment. The graph shows the mean change from baseline for placebo and memantine hydrochloride groups. The x-axis shows weeks of treatment while the y-axis shows the SIB score.*

The text describes a figure labeled "Figure 4", which shows the cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB (Severe Impairment Battery) scores. The figure compares the effectiveness of two treatments, Placebo and Memantine Hydrochloride.*

The text is describing a figure showing the time course of change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment with either Placebo/Donepezil or Memantine Hydrochloride/Donepezil. The figure shows that Memantine Hydrochloride/Donepezil resulted in a clinical improvement while Placebo/Donepezil did not. The text also mentions "Mean (+SEM) Change from Baseline" but no specific information is provided.*

This is a graph that shows the cumulative percentage of patients who completed 24 weeks of double-blind treatment with the specified changes from baseline in ADCS-ADL scores. The graph compares two treatments: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. There are no other details available to provide.*

The text provides a graph displaying the time course of the change from baseline in SIB score for patients completing 24 weeks of treatment. The SIB score is evaluated in the context of Placebo/Donepezil Clinical Dectn and Memantine Hydrochloride/Donepezil treatments. The mean change from baseline is also presented.*

The text describes a figure labeled "Figure 8" that shows the percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in SIBscores. The figure displays two treatment groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis shows a range of scores from 20 to -30, and the y-axis shows the cumulative percentage of patients.*

Memantine is a prescription medication with 10mg tablets containing memantine hydrochloride, intended for control of symptoms of dementia. It must be kept in storage between 20 to 25°C (66-77°F), with allowable excursions in temperature from 15-30°C (56-86°F). The medication is packaged by Contract Pharmacy Services and contains a lot number and expiration date. Further dosage information is present in the accompanying prescribing documentation. *